ABT
Abbott Laboratories
ABT's fundamentals are mixed, but it looks expensive: trading at 40x earnings, above its usual 33x. Its downside scenario is about three times its upside.
ABT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Healthy | |
| Under pressure |
ABT's revenue and cash flow are currently healthy, and its profitability is stable, but its balance sheet is under pressure.
ABT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $107 | — |
| Cheap | 22x | $58.67 | -45% |
| Fair | 33x | $88.57 | -17% |
| Current | 40x | $107 | — |
| Expensive | 45x | $121 | +13% |
Historical ranges are pointers, not guarantees.
ABT's PE is in its expensive range at 40x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ABT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for ABT, with profitability holding steady.
ABT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.84 | +118% |
| Q3 2026 | $2.68 | -66% |
| Q2 2026 | $3.09 | -61% |
| Q1 2026 | $3.57 | -54% |
| Q4 2025 | $3.72 | -51% |
| Q3 2025 | $7.97 | +142% |
| Q2 2025 | $7.97 | +151% |
| Q1 2025 | $7.70 | +140% |
| Q4 2024 | $7.64 | +134% |
ABT's earnings per share have fallen from their peak: $2.68 over the past year, against $7.97 in mid-2025.
ABT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13B | +14% |
| Q2 2026 | $12.6B | +13% |
| Q1 2026 | $11.2B | +7.8% |
| Q4 2025 | $11.5B | +4.4% |
| Q3 2025 | $11.4B | +6.9% |
| Q2 2025 | $11.1B | +7.4% |
| Q1 2025 | $10.4B | +4% |
| Q4 2024 | $11B | +7.2% |
ABT's revenue has grown year over year for 12 quarters in a row: $13B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | -7.7 points |
| Q2 2026 | 13% | -5 points |
| Q1 2026 | 12% | -4.3 points |
| Q4 2025 | 20% | +2.2 points |
| Q3 2025 | 18% | +0.6 points |
| Q2 2025 | 18% | +2.3 points |
| Q1 2025 | 16% | +2.4 points |
| Q4 2024 | 17% | 0 points |
ABT's operating margin was 10% last quarter, down 7.7 points from the same quarter a year ago, near the bottom of its range since 2019.
ABT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | -47% |
| Q2 2026 | $2B | +29% |
| Q1 2026 | $916M | -1.8% |
| Q4 2025 | $2.6B | +22% |
| Q3 2025 | $2.3B | +6.6% |
| Q2 2025 | $1.5B | +8.3% |
| Q1 2025 | $933M | +49% |
| Q4 2024 | $2.1B | -5.9% |
ABT's free cash flow has been positive every quarter for seven years: $6.8B over the past year, down 2.3% from the year before.
ABT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -5.1M shares |
| 1 year | -0.7% | -11.5M shares |
| 3 years | -0.6% | -10.4M shares |
| 5 years | -2.9% | -51.1M shares |
| Available history | -2.4% | -43.1M shares |
ABT has 1.7B diluted shares, down 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $11M |
| Q2 2026 | $1B |
| Q1 2026 | $180M |
| Q4 2025 | $302M |
| Q3 2025 | $305M |
| Q2 2025 | $6M |
| Q1 2025 | $280M |
| Q4 2024 | $315M |
ABT spent $1.5B buying back its own shares over the past year, up 70% from the year before.
ABT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.6x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.6x | Very low |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 0.7x | Very low |
ABT's net debt is about 2.6 years of its operating earnings (EBITDA), up from less than a year a year ago.
ABT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.0 | Neutral |
| Stochastic | 57.1 | Neutral |
ABT's weekly RSI is 54 (neutral) and its Stochastic is 57 (neutral).
ABT PE vs Healthcare Sector
| Metric | ABT | Sector median | Relative |
|---|---|---|---|
| PE | 40x | 26x | 55% above |
| PE % | 81 | 29 | 52 pts above |
ABT is trading at 40x earnings, a 55% premium to the Healthcare sector's median of 26x.
ABT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $103.8 | 3.3% above |
| 20 week MA | $104.5 | 2.6% above |
| 50 week MA | $104.9 | 2.3% above |
| 100 week MA | $117.0 | 8.4% below |
| 200 week MA | $112.4 | 4.6% below |
ABT has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 4.6% below its 200-week average.
ABT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $87.4 | $108.4 | +24% |
| 2021 | $108.4 | $139.2 | +28% |
| 2022 | $139.2 | $108.2 | -22% |
| 2023 | $108.2 | $110.1 | +1.7% |
| 2024 | $110.1 | $115.0 | +4.5% |
| 2025 | $115.0 | $124.8 | +8.6% |
| 2026 YTD | $124.8 | $107.3 | -14% |
ABT has finished higher in five of the last six years. It's down 14% so far in 2026.